Beam Therapeutics Inc.

CRL AI-extracted

BEAM-304

phenylketonuria (PKU)

Date

TBD

FDA decision · Date TBD estimated

What's at stake An FDA complete response letter on BEAM-304 for phenylketonuria (PKU) is in focus around Date TBD.

Primary source · SEC 8-K verified 13h ago

“Beam expects to file an investigational new drug (IND) application with the FDA for BEAM-304 in 2026 following completion of pre-IND activities.”